CMPS
COMPASS Pathways plc- Healthcare
- Biotechnology
- $1.55B market cap
Forecast run · Oct 29, 2026Upside rank 441 of 3,186
Model Signal
ForecastQ Daily Probabilities
46.8%
65.2%
26.8%
Analyst Consensus
Recommendation2.00/5 Buy
Last price$11.18
Price target$18.63
Implied move+66.6%
Analysts15
ForecastQ Portfolios
CMPS is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.